14 results
425
EX-10.3
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
. Holder hereby agrees and acknowledges that Hepion and the Company, would be irreparably injured in the event of a breach by Holder of its, his
8-K
EX-10.3
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
. Holder hereby agrees and acknowledges that Hepion and the Company, would be irreparably injured in the event of a breach by Holder of its, his
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals, Inc.
24 Jul 23
Regulation FD Disclosure
4:04pm
Three Primary Cyclophilins Rencofilstat blocks Cyclophilin D activation of mitochondrial membrane pores and thereby decreases cell death in injured
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals, Inc.
22 May 23
Regulation FD Disclosure
1:05pm
in injured livers CYTOPROTECTIVE 13 Rencofilstat blocks Cyclophilin A binding to CD147 receptors and thereby decreases pro-inflammatory signaling ANTI
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals, Inc.
17 Oct 22
Regulation FD Disclosure
5:13pm
and thereby decreases cell death in injured livers CYTOPROTECTIVE 7 Rencofilstat blocks Cyclophilin A binding to CD147 receptors and thereby decreases pro
8-K
EX-99.1
960iu8t8lg 3vtgiy7
27 May 22
Regulation FD Disclosure
8:44am
8-K
EX-99.1
lxw5s9k
30 Sep 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
5:22pm
8-K
EX-99.2
bkc96p3
13 Sep 21
Regulation FD Disclosure
8:28am
FWP
64npl8 w7mr8
12 Feb 21
Free writing prospectus
5:29pm
8-K
EX-99.1
h51a6 v37
28 Jan 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES JANUARY 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
4:30pm
FWP
h46 rcd39rox
18 Nov 20
Free writing prospectus
5:29pm
FWP
z908 9p78cyd4
12 Nov 20
Free writing prospectus
5:27pm
8-K
EX-99.1
nl3w2p6fe sb
1 Oct 20
Regulation FD Disclosure
4:27pm
8-K
EX-99.1
vfukz25u
20 Feb 20
Other Events
9:12am
- Prev
- 1
- Next